CLEC10A and neoplasm: Targeting HML-2 with antiretroviral drugs reduces reverse transcriptase activity, tumor viability, and pluripotency, suggesting that HML-2 contributes fundamentally to the GSC niche and may serve as a unique therapeutic target [67].